Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N; CheckMate 816 Investigators. Forde PM, et al. N Engl J Med. 2022 May 26;386(21):1973-1985. doi: 10.1056/NEJMoa2202170. Epub 2022 Apr 11. N Engl J Med. 2022. PMID: 35403841 Free PMC article. Clinical Trial.
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators. Khorana AA, et al. N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630. N Engl J Med. 2019. PMID: 30786186 Clinical Trial.
Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22 - April 30, 2020.
ICMR COVID Study Group (In alphabetical order: Priya Abraham†, Neeraj Aggarwa l2, Giridhara R. Babu 7, Suganya Barani 8, Balram Bhargava 4, Tarun Bhatnagar 8, Ajay Singh Dhama 3, Raman R. Gangakhedkar 2, Sidhartha Giri 2, Nivedita Gupta 2, Karishma K. Kurup 5, Ponnaiah Manickam 9, Manoj Murhekar ††, Varsha Potdar 1, Ira Praharaj 2, Kiran Rade 6, D.C.S. Reddy 11, V. Saravanakumar 10, Naman Shah 12, Harpreet Singh 3, Jeromie Wesley Vivian Thangaraj 8, Naveen Yadav 8), COVID Epidemiology & Data Management Team @, COVID Laboratory Team*, VRDLN Team$; @COVID Epidemiology & Data Management Team (in alphabetical order): Tanu Anand, Harish Kumar Butollia, Pranab Chatterjee, Himanshu Chauhan, R Deepa, Amirthammal Gunasekaran, Daisy A John, Shashi Kant, Sanket Kulkarni, Vinit Kumar, JP Muliyil, Ravindra Mohan Pandey, Swarup Sarkar, Sujeet Singh, Sanjay Zodpey; *COVID Laboratory Team (in alphabetical order): Srima Adhikari, Jyotsna Agarwal, Naveen KumarAgarwal, Saurabh G Agarwal, Prerna Aggarwal, Anurag Agrawal, Arti Agrawal, Safaa Muneer Ahmed, G Ambernath, Nitin Ambhore, VP Amudha, Sohini Arora, Ashok, Anita, Awanti, Veer Badriyah TA, Amrita Kumari B, Maneesh Bagai, Dipa Baido, Bai… See abstract for full author list ➔ ICMR COVID Study Group (In alphabetical order: Priya Abraham†, Neeraj Aggarwa l2, Giridhara R. Babu 7, Suganya Barani 8, Balram Bhargava 4, Tarun Bhatnagar 8, Ajay Singh Dhama 3, Raman R. Gangakhedkar 2, Sidhartha Giri 2, Nivedita Gupta 2, Karishma K. Kurup 5, Ponnaiah Manickam 9, Manoj Murhekar ††, Varsha Potdar 1, Ira Praharaj 2, Kiran Rade 6, D.C.S. Reddy 11, V. Saravanakumar 10, Naman Shah 12, Harpreet Singh 3, Jeromie Wesley Vivian Thangaraj 8, Naveen Yadav 8), COVID Epidemiology & Data Management Team @, COVID Laboratory Team*, VRDLN Team$, et al. Indian J Med Res. 2020 May;151(5):424-437. doi: 10.4103/ijmr.IJMR_1896_20. Indian J Med Res. 2020. PMID: 32611914 Free PMC article.
INTERPRETATION & CONCLUSIONS: The coverage and frequency of ICMR's laboratory surveillance for SARS-CoV-2 improved over time. COVID-19 was reported from most parts of India, and the attack rate was more among men and the elderly and common among close contacts. ...
INTERPRETATION & CONCLUSIONS: The coverage and frequency of ICMR's laboratory surveillance for SARS-CoV-2 improved over time. COV …